Cargando…
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
INTRODUCTION: Mucin 1 (MUC1) is a high molecular weight glycoprotein overexpressed on adenocarcinoma cells and is a target for immunotherapy protocols. To date, clinical trials against MUC1 have included advanced cancer patients. Herein, we report a trial using early stage breast cancer patients and...
Autores principales: | Apostolopoulos, Vasso, Pietersz, Geoffrey A, Tsibanis, Anastasios, Tsikkinis, Annivas, Drakaki, Heleni, Loveland, Bruce E, Piddlesden, Sara J, Plebanski, Magdalena, Pouniotis, Dodie S, Alexis, Michael N, McKenzie, Ian F, Vassilaros, Stamatis |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1557739/ https://www.ncbi.nlm.nih.gov/pubmed/16776849 http://dx.doi.org/10.1186/bcr1505 |
Ejemplares similares
-
Dendritic cell immunotherapy: clinical outcomes
por: Apostolopoulos, Vasso, et al.
Publicado: (2014) -
Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope
por: Brooks, Nicole, et al.
Publicado: (2018) -
Comparative Immunogenicity of a Cytotoxic T Cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides
por: Brooks, Nicole, et al.
Publicado: (2015) -
Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients
por: Kuol, Nyanbol, et al.
Publicado: (2022) -
Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan
por: Matsoukas, John M., et al.
Publicado: (2021)